Subdermal Contraceptive Implants Market - Forecast(2024 - 2030)

Subdermal Contraceptive Implants market size was estimated at $780 million in 2020, growing at a CAGR of 3.35% during the forecast period 2021-2026. Subdermal contraceptive implants are those in which a steroid progestin is delivered by polymer capsules or rods implanted beneath the skin. The hormone diffuses slowly and steadily, giving effective contraception for 1 to 5 years. The duration of protection is determined by the type of progestin used and the type of polymer used. Subdermal contraceptive implants are simple to use and provide excellent results. It is a 4-cm single-rod implant that can be put subdermally through a trocar. There are two types of subdermal contraceptive implant such as levonorgestrel implant, and etonogestrel implant. If a female waits more than three years to replace her rod, her chances of becoming pregnant increase. It is a 4-cm single-rod implant that can be put subdermally through a trocar. The disadvantage of the implant is disruption of normal menstruation and an increase in breast pain. The increasing number of unwanted pregnancy and abortion is the major factors driving the growth of the market. Increasing awareness about sexual health and family planning is set to further enhance the overall market development of the Subdermal Contraceptive Implants Market for the period 2021-2026.

The report: “Subdermal Contraceptive Implants Market Forecast (2021-2026)”, by Industry ARC, covers an in-depth analysis of the following segments of the Subdermal Contraceptive Implants Market.

By Type: Etonogestrel Implant, and Levonorgestrel Implant

By End-User: Hospitals, Clinics, Diagnostic Centres and Others.

By Geography: North America (U.S., Canada, Mexico), Europe (Germany, U.K., France, Italy, Spain, Russia, and Rest of Europe), Asia Pacific (China, Japan India, South Korea, Australia, and New Zealand, and Rest of Asia Pacific), South America (Brazil, Argentina, and Rest of South America), and Rest of the World (Middle East, and Africa)

Based on type, the Subdermal Contraceptive Implants market is segmented into Etonogestrel Implant, and Levonorgestrel Implant. Etonogestrel Implant held the largest share and is also estimated to register a higher CAGR of 4.1% during the forecast period 2021-2026. Etonogestrel is a birth control medicine for women. Etonogestrel (a drug type that comes under progestin medical class) is a hormone that inhibits ovulation from taking place. It is offered as an implant that is inserted beneath the skin of the upper arm. The implant is non-biodegradable, off-white, and 4 cm long with a 2 mm diameter. Each implant is made up of an ethylene vinylacetate (EVA) copolymer core containing 68 mg of etonogestrel, a synthetic progestin, and an EVA copolymer skin thereby increasing Subdermal Contraceptive Implants market. 

On the basis of application market for Subdermal Contraceptive Implants is categorized in Hospitals, Clinics, Diagnostic Centres and Others. Hospitals held the largest share and it is estimated to register a CAGR of 4.3% during the forecast period 2021-2026. Hospitals offer high-traffic environments, advanced healthcare infrastructure, innovative medical equipment and services, and the presence of competent medical experts in hospitals thereby increasing Subdermal Contraceptive Implants market. 

The increasing number of unwanted pregnancies leads to rise in abortions and is therefore increasing the growth of the Subdermal Contraceptive Implants Market. According to the World Health Organization's 2019 report, 74 million women in low and middle-income countries experience unwanted pregnancies each year. Every year, this results in 25 million unsafe abortions and 47000 maternal deaths. Additionally, increase in adoption rate of contraceptive drugs is also practiced to increase the growth of the Subdermal Contraceptive Implants market during the forecast period 2021-2026. 

Increasing government initiatives to spread awareness about unwanted abortions and pregnancies is increasing the growth of the Subdermal Contraceptive Implants market. Certain countries and their governments have recognised the need to reduce the number of unwanted pregnancies and have launched a projects to educate and prevent the spread of unwanted pregnancies and abortions. For Instance, FDA-approved birth control products are covered by Medicaid and other insurance plans without cost sharing thereby increasing the growth of the Subdermal Contraceptive Implants Market during the forecast period 2021-2026.

Major factor that is set to impede the growth of the Subdermal Contraceptive Implants market is side effects of subdermal contraceptive implants are disruption of normal menstruation and increase in breast pain. Another factor which hamper the growth of market is increasing rate of infertility.

Product launches, mergers and acquisitions, joint ventures, and R&D activities are key strategies adopted by players in the Subdermal Contraceptive Implants Market. In 2020, the Subdermal Contraceptive Implants Market share is consolidated by the top ten players present in the market. The Subdermal Contraceptive Implants Market, top 10 companies are, Bayer AG, Shanghai Dahua Pharmaceutical Co., Ltd., Merck Sharp & Dohme Corp., Karex Industries, Teva Pharmaceutical Industries Ltd., Allergan plc, The Female Health Company, Reckitt Benckiser Group plc, KESSEL medintim GmbH and Mayer Laboratories.